Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-1513 · 1 trial · 3 indications
Count of events
| Arm | Type | Description |
|---|---|---|
| NNC9204-1513 | EXPERIMENTAL | Participants will receive increasing doses of NNC9204-1513. |
| Glucagon | ACTIVE_COMPARATOR | Participants will receive a single fixed dose of glucagon. |
| Name | Type | Description |
|---|---|---|
| NNC9204-1513 | DRUG | Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose. Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group. |
| Glucagon | DRUG | Participants will receive single dose of 1 mg glucagon s.c. injection. |
| Placebo | DRUG | Participants will receive single dose of placebo (for double dummy injections). |
Inclusion Criteria: * Male, aged 18 -55 years (both inclusive), at the time of signing informed consent * Body mass index (BMI) between 18.5 and 28.0 kg/sqm (both inclusive) * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC9204-1513 is an investigational small molecule being developed by Novo Nordisk for the treatment of diabetes, including type 1 and type 2 diabetes mellitus. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The molecular target of NNC9204-1513 has not been disclosed in available information. It is a small molecule being studied for its potential effects in diabetes, but its specific mechanism of action is not publicly detailed.
NNC9204-1513 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the drug's safety and efficacy in diabetes.
NNC9204-1513 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies and is still undergoing clinical trials to assess its safety and potential effectiveness in treating diabetes.
NNC9204-1513 has one completed Phase 1 clinical trial, identified as NCT03444467. This study compared the drug to glucagon in healthy male participants in Germany, with a total enrollment of 36 individuals. The trial was randomized, double-blind, and active-controlled.
No, NNC9204-1513 is not the same as glucagon. In a clinical trial, NNC9204-1513 was compared to glucagon as an active control, indicating they are distinct substances. The study aimed to evaluate how the new medicine compares to glucagon in healthy people.